Astrazeneca (AZN) Other financing activities (2009 - 2026)

Astrazeneca (AZN) has reported Other financing activities for 17 consecutive years, with $2.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities rose 112.37% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $1.6 billion (up 2286.57% YoY), while the FY2025 annual figure was $364.0 million, up 1274.19% from the prior year.
• Other financing activities came in at $2.3 billion for Q1 2026 at Astrazeneca, up from -$1.0 billion in the prior quarter.
• The five-year high for Other financing activities was $2.3 billion in Q1 2026, with the low at -$1.9 billion in Q3 2024.
• Average Other financing activities over 5 years is $235.0 million, with a median of $97.0 million recorded in 2023.
• Across the five-year window, Other financing activities plunged 266.67% in 2023 and soared 6108.0% in 2024, its largest moves.
• Year by year, Other financing activities stood at $15.0 million in 2022, then slumped by 266.67% to -$25.0 million in 2023, then slumped by 2312.0% to -$603.0 million in 2024, then tumbled by 68.82% to -$1.0 billion in 2025, then soared by 329.27% to $2.3 billion in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $2.3 billion, -$1.0 billion, and -$352.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.